The source exists and the post reproduces it faithfully. Bloomberg reported that in a mid-stage study, Insilico Medicine's drug rentosertib helped reduce biological age as measured by six different aging clocks examining chemical changes in the body, according to an analysis published in Nature Biotechnology .

The underlying analysis was a secondary examination of blood samples from an already-completed trial. The analysis drew on serum proteome data from a randomized, double-blind, placebo-controlled Phase IIa trial of rentosertib in idiopathic pulmonary fibrosis, conducted across sites in China in 2023 and 2024.

Of the trial's participants, 42 consented to longitudinal proteomic profiling at baseline, week 2, week 4, and week 12, covering 2,841 proteins measured with the Olink Explore 3072 panel.

The reported result is a consensus across models rather than a single measurement: analyzing 12-week longitudinal Olink proteomic data from 42 IPF patients, six aging clock models including ProtAge, OrganAge, and PAC, independently developed by groups from Harvard, Oxford, PKU, and Insilico, unanimously indicated that rentosertib reversed predicted biological age.

Every clock recorded a reduction in predicted biological age in the treatment arms relative to placebo over the 12-week period.

The company also links this to a lung-function signal: Forced Vital Capacity, the measure of lung function that declines with age, showed dose-dependent reversal compared with placebo, aligning with the proteomic aging clock results.

METHODOLOGY AND CONTEXT

Parent trial design. The Phase 2a was a multicenter, double-blind, randomized, placebo-controlled trial of rentosertib, a first-in-class AI-generated small-molecule TNIK inhibitor, in IPF.

Patients were randomized to 12 weeks of treatment with 30 mg once daily (n = 18), 30 mg twice daily (n = 18), 60 mg once daily (n = 18), or placebo (n = 17). The primary endpoint was the percentage of patients with at least one treatment-emergent adverse event.

Critical point on the primary endpoint: the trial was designed and powered for safety, not efficacy and not aging. Of 128 patients screened, 71 were randomized, and sixteen patients discontinued treatment prior to the end of treatment.

Lung function figures. At 12 weeks, placebo-treated patients showed a mean FVC decline of -62.3 mL (95% CI: -115.3 to -9.33). The 30 mg QD group had reduced decline (-37.5 mL; -100.8 to 25.7), while 30 mg BID and 60 mg QD groups showed FVC improvements: +19.7 mL (-60.5 to 99.9) and +98.4 mL (10.9 to 185.9), respectively. Note that two of the four arms have confidence intervals crossing zero.

Regulatory status of the biomarker. The authors themselves treat aging clocks as not yet qualified endpoints. The research proposes a stepwise framework: collecting aging and senescence biomarkers prospectively as exploratory endpoints in disease trials, and ultimately pursuing biomarker qualification or composite clinical endpoints under the FDA Biomarker Qualification Program and FDA-NIH BEST framework. A framework for future qualification is, by definition, not a qualified endpoint today.

Conflict of interest. The results were to be presented by first author Alex Zhavoronkov, founder and CEO of Insilico Medicine. The company's CEO is the first author of the paper evaluating the company's own drug, and the same press release promotes corporate financials: Insilico reported total revenue of approximately $106 million in the first half of 2026, a 287% year-over-year increase, and achieved its first profitable half-year since listing.

Data availability (a point in the study's favor). All proteomic data from the study have been deposited with the China National Center for Bioinformation under accession OMIX008341.

Secondary claim on repurposing. This is well supported as background. The Metformin In Longevity Study and the TAME trial are large-scale clinical studies designed to evaluate metformin's ability to delay multiple age-related comorbidities in 3,000 non-diabetic older adults, with results still pending.

A curated list of 17 compounds under clinical trial for healthy longevity includes well-known candidates such as metformin and sirolimus (rapamycin).